<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28526722</article-id><article-id pub-id-type="pmc">5469596</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0059</article-id><article-id pub-id-type="publisher-id">ONCO12154</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>14</subject><subject>31</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>Phase II Study of Modified Carboplatin Plus Weekly Nab&#x02010;Paclitaxel in Elderly Patients with Non&#x02010;Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301</article-title></title-group><contrib-group><contrib id="onco12154-cr-0001" contrib-type="author" corresp="yes"><name><surname>Miyauchi</surname><given-names>Eisaku</given-names></name><address><email>miyauchi@rm.med.tohoku.ac.jp</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12154-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12154-cr-0002" contrib-type="author"><name><surname>Inoue</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="onco12154-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12154-cr-0003" contrib-type="author"><name><surname>Usui</surname><given-names>Kazuhiro</given-names></name><xref ref-type="aff" rid="onco12154-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12154-cr-0004" contrib-type="author"><name><surname>Sugawara</surname><given-names>Shunichi</given-names></name><xref ref-type="aff" rid="onco12154-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12154-cr-0005" contrib-type="author"><name><surname>Maemondo</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="onco12154-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12154-cr-0006" contrib-type="author"><name><surname>Saito</surname><given-names>Heisuke</given-names></name><xref ref-type="aff" rid="onco12154-aff-0006"><sup>f</sup></xref></contrib><contrib id="onco12154-cr-0007" contrib-type="author"><name><surname>Fujita</surname><given-names>Yuka</given-names></name><xref ref-type="aff" rid="onco12154-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12154-cr-0008" contrib-type="author"><name><surname>Kato</surname><given-names>Terufumi</given-names></name><xref ref-type="aff" rid="onco12154-aff-0008"><sup>h</sup></xref></contrib><contrib id="onco12154-cr-0009" contrib-type="author"><name><surname>Suzuki</surname><given-names>Toshiro</given-names></name><xref ref-type="aff" rid="onco12154-aff-0009"><sup>i</sup></xref></contrib><contrib id="onco12154-cr-00010" contrib-type="author"><name><surname>Harada</surname><given-names>Toshiyuki</given-names></name><xref ref-type="aff" rid="onco12154-aff-0010"><sup>j</sup></xref></contrib><contrib id="onco12154-cr-00011" contrib-type="author"><name><surname>Watanabe</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="onco12154-aff-0011"><sup>k</sup></xref></contrib><contrib id="onco12154-cr-00012" contrib-type="author"><name><surname>Nakagawa</surname><given-names>Taku</given-names></name><xref ref-type="aff" rid="onco12154-aff-0012"><sup>l</sup></xref></contrib><contrib id="onco12154-cr-00013" contrib-type="author"><name><surname>Ichinose</surname><given-names>Masakazu</given-names></name><xref ref-type="aff" rid="onco12154-aff-0001"><sup>a</sup></xref></contrib><aff id="onco12154-aff-0001"><label><sup>a</sup></label><named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Tohoku University Graduate School of Medicine</institution>, <city>Sendai</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0002"><label><sup>b</sup></label>
<named-content content-type="organisation-division">Department of Palliative Medicine</named-content>, <institution>Tohoku University School of Medicine</institution>, <city>Senadi</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0003"><label><sup>c</sup></label>
<named-content content-type="organisation-division">Division of Respirology</named-content>, <institution>NTT Medical Center Tokyo</institution>, <state>Tokyo</state>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0004"><label><sup>d</sup></label>
<named-content content-type="organisation-division">Department of Pulmonary Medicine</named-content>, <institution>Sendai Kousei Hospital</institution>, <city>Sendai</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0005"><label><sup>e</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Miyagi Cancer Center</institution>, <city>Natori</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0006"><label><sup>f</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Iwate Medical University Hospital</institution>, <city>Morioka</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0007"><label><sup>g</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Asahikawa Medical Center</institution>, <city>Asahikawa</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0008"><label><sup>h</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Kanagawa Cardiovascular and Respiratory Center</institution>, <city>Yokohama</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0009"><label><sup>i</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Isawa Hospital</institution>, <city>Fuefuki</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0010"><label><sup>j</sup></label><institution>Center for Respiratory Diseases</institution>,
<named-content content-type="organisation-division"> JCHO Hokkaido Hospital</named-content>, <city>Sapporo</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0011"><label><sup>k</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>, <institution>Saka General Hospital</institution>, <city>Shiogama</city>, <country country="JP">Japan</country>
</aff><aff id="onco12154-aff-0012"><label><sup>l</sup></label><institution>Thoracic Surgery, Omagari&#x02010;Kosei Medical Center</institution>, <city>Daisen</city>, <country country="JP">Japan</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Eisaku Miyauchi, M.D., Ph.D., Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1&#x02010;1, Seiryo&#x02010;machi, Aoba&#x02010;ku, Sendai, Miyagi, Sendai, Japan 980&#x02010;8574. Telephone: 81&#x02010;22&#x02010;717&#x02010;8539; e&#x02010;mail: <email>miyauchi@rm.med.tohoku.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>5</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>6</issue><issue-id pub-id-type="doi">10.1002/onco.v22.6</issue-id><fpage>640</fpage><lpage>e59</lpage><history><date date-type="received"><day>25</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">&#x000a9; AlphaMed Press; the data published online to support this summary is the property of the authors.</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12154.pdf"/><abstract><title>Abstract</title><sec id="onco12154-sec-1351"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12154-list-0002"><list-item id="onco12154-li-0100"><p>Weekly nanoparticle albumin&#x02010;bound&#x02010;paclitaxel (75 mg/m<sup>2</sup>) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non&#x02010;small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity.</p></list-item><list-item id="onco12154-li-0101"><p>This modified regimen offers potential for the treatment of elderly patients.</p></list-item></list></p></sec><sec id="onco12154-sec-0222"><title>Background.</title><p>The CA031 trial suggested weekly nanoparticle albumin&#x02010;bound&#x02010;paclitaxel (nab&#x02010;PTX) was superior in efficacy to paclitaxel (PTX) once every 3 weeks when combined with carboplatin (CBDCA) for advanced non&#x02010;small cell lung cancer (NSCLC) patients; a subgroup analysis of elderly patients looked promising. In a multicenter phase II trial, we prospectively evaluated the efficacy and tolerability of modified CBDCA plus weekly nab&#x02010;PTX for elderly patients with untreated advanced NSCLC.</p></sec><sec id="onco12154-sec-4222"><title>Methods.</title><p>Eligible patients received CBDCA (area under the curve [AUC] 6 mg/mL/min) on day 1 and nab&#x02010;PTX (75 mg/m<sup>2</sup>) on days 1, 8, and 15 every 4 weeks. The primary endpoint was an overall response rate (ORR), and secondary endpoints were progression&#x02010;free survival (PFS), overall survival (OS), and toxicity.</p></sec><sec id="onco12154-sec-4245"><title>Results.</title><p>Of 32 patients (median age of 78 years), 84% were male, 56% had stage IV NSCLC, and 56% had squamous cell carcinoma. ORR and disease control rates were 50% (95% confidence interval (CI): 33&#x02013;67) and 94% (95% CI: 85&#x02013;100), respectively. Median PFS and OS were 6.4 months (95% CI: 4.8&#x02013;8.0) and 17.5 months (95% CI: 11.9&#x02013;23.1), respectively. Grade &#x02265;3 toxicities were neutropenia (47%), leukopenia (38%), anemia (34%), thrombocytopenia (25%), and anorexia (9%). Febrile neutropenia and treatment&#x02010;related deaths were not observed.</p></sec><sec id="onco12154-sec-8245"><title>Conclusion.</title><p>Modified CBDCA plus weekly nab&#x02010;PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh">&#x07ecf;&#x09a8c;&#x0603b;&#x07ed3;</p><p xml:lang="zh">&#x02022; &#x0767d;&#x086cb;&#x0767d;&#x07ed3;&#x05408;&#x0578b;&#x07d2b;&#x06749;&#x09187;&#x07eb3;&#x07c73;&#x09897;&#x07c92;&#x0ff08;75 mg/m<sup>2</sup>&#x0ff09;&#x06bcf;&#x05468;&#x04e00;&#x06b21;&#x07ed9;&#x0836f;&#x08054;&#x05408;&#x05361;&#x094c2;&#x0ff08;&#x066f2;&#x07ebf;&#x04e0b;&#x09762;&#x079ef;6 mg/mL/min&#x0ff09;&#x06cbb;&#x07597;&#x065e2;&#x05f80;&#x0672a;&#x07ecf;&#x06cbb;&#x07597;&#x07684;&#x0665a;&#x0671f;&#x0975e;&#x05c0f;&#x07ec6;&#x080de;&#x080ba;&#x0764c;&#x08001;&#x05e74;&#x060a3;&#x08005;&#x065f6;&#x07597;&#x06548;&#x0548c;&#x08010;&#x053d7;&#x06027;&#x0826f;&#x0597d;, &#x04e14;&#x0795e;&#x07ecf;&#x06bd2;&#x06027;&#x08f83;&#x04f4e;&#x03002;</p><p xml:lang="zh">&#x02022; &#x08fd9;&#x04e00;&#x06539;&#x0826f;&#x065b9;&#x06848;&#x05728;&#x08001;&#x05e74;&#x060a3;&#x08005;&#x07684;&#x06cbb;&#x07597;&#x04e2d;&#x05177;&#x06709;&#x06f5c;&#x05728;&#x05e94;&#x07528;&#x04ef7;&#x0503c;&#x03002;</p><p xml:lang="zh">&#x06458;&#x08981;</p><p xml:lang="zh"><bold><italic>&#x080cc;&#x0666f;</italic>.</bold> CA031&#x08bd5;&#x09a8c;&#x08868;&#x0660e;, &#x04e0e;&#x05361;&#x094c2;&#x0ff08;CBDCA&#x0ff09;&#x08054;&#x05408;&#x06cbb;&#x07597;&#x0665a;&#x0671f;&#x0975e;&#x05c0f;&#x07ec6;&#x080de;&#x080ba;&#x0764c;&#x0ff08;NSCLC&#x0ff09;&#x060a3;&#x08005;&#x065f6;, &#x0767d;&#x086cb;&#x0767d;&#x07ed3;&#x05408;&#x0578b;&#x07d2b;&#x06749;&#x09187;&#x07eb3;&#x07c73;&#x09897;&#x07c92;&#x0ff08;nab&#x02010;PTX, &#x06bcf;&#x05468;&#x04e00;&#x06b21;&#x0ff09;&#x07684;&#x07597;&#x06548;&#x04f18;&#x04e8e;&#x07d2b;&#x06749;&#x09187;&#x0ff08;PTX, &#x06bcf;3&#x05468;&#x04e00;&#x06b21;&#x0ff09;&#x0ff1b;&#x08001;&#x05e74;&#x060a3;&#x08005;&#x07684;&#x04e9a;&#x07ec4;&#x05206;&#x06790;&#x0663e;&#x0793a;&#x08be5;&#x065b9;&#x06848;&#x0524d;&#x0666f;&#x0826f;&#x0597d;&#x03002;&#x05728;&#x04e00;&#x09879;&#x0591a;&#x04e2d;&#x05fc3;II&#x0671f;&#x08bd5;&#x09a8c;&#x04e2d;, &#x06211;&#x04eec;&#x0524d;&#x077bb;&#x06027;&#x08bc4;&#x04ef7;&#x04e86;CBDCA&#x08054;&#x05408;&#x06bcf;&#x05468;&#x04e00;&#x06b21;nab&#x02010;PTX&#x06539;&#x0826f;&#x065b9;&#x06848;&#x06cbb;&#x07597;&#x0672a;&#x07ecf;&#x06cbb;&#x07597;&#x07684;&#x0665a;&#x0671f;NSCLC&#x08001;&#x05e74;&#x060a3;&#x08005;&#x07684;&#x07597;&#x06548;&#x0548c;&#x08010;&#x053d7;&#x06027;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x065b9;&#x06cd5;</italic>.</bold> &#x05408;&#x0683c;&#x060a3;&#x08005;&#x05728;&#x06bcf;4&#x05468;&#x07684;&#x07b2c;1&#x05929;&#x063a5;&#x053d7;CBDCA[&#x066f2;&#x07ebf;&#x04e0b;&#x09762;&#x079ef;&#x0ff08;AUC&#x0ff09;6 mg/mL/min], &#x05e76;&#x05728;&#x07b2c;1&#x03001;8&#x0548c;15&#x05929;&#x063a5;&#x053d7;nab&#x02010;PTX&#x0ff08;75 mg/m<sup>2</sup>&#x0ff09;&#x03002;&#x04e3b;&#x08981;&#x07ec8;&#x070b9;&#x04e3a;&#x0603b;&#x07f13;&#x089e3;&#x07387;&#x0ff08;ORR&#x0ff09;, &#x06b21;&#x08981;&#x07ec8;&#x070b9;&#x04e3a;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;PFS&#x0ff09;&#x03001;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;OS&#x0ff09;&#x0548c;&#x06bd2;&#x06027;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x0679c;</italic>.</bold> 32&#x04f8b;&#x060a3;&#x08005;&#x0ff08;&#x04e2d;&#x04f4d;&#x05e74;&#x09f84;78&#x05c81;&#x0ff09;&#x04e2d;&#x06709;84%&#x04e3a;&#x07537;&#x06027;, 56%&#x060a3;&#x06709;IV&#x0671f;NSCLC, 56%&#x060a3;&#x06709;&#x09cde;&#x072b6;&#x07ec6;&#x080de;&#x0764c;&#x03002;ORR&#x0548c;&#x075be;&#x075c5;&#x063a7;&#x05236;&#x07387;&#x05206;&#x0522b;&#x04e3a;50%[95%&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff08;CI&#x0ff09;&#x0ff1a;33&#x02010;67]&#x0548c;94%&#x0ff08;95% CI&#x0ff1a;85&#x02010;100&#x0ff09;&#x03002;&#x04e2d;&#x04f4d;PFS&#x0548c;OS&#x05206;&#x0522b;&#x04e3a;6.4&#x04e2a;&#x06708;&#x0ff08;95% CI&#x0ff1a;4.8&#x02010;8.0&#x0ff09;&#x0548c;17.5&#x04e2a;&#x06708;&#x0ff08;95% CI&#x0ff1a;11.9&#x02010;23.1&#x0ff09;&#x03002;&#x02265;3&#x07ea7;&#x06bd2;&#x06027;&#x05305;&#x062ec;&#x04e2d;&#x06027;&#x07c92;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x075c7;&#x0ff08;47%&#x0ff09;&#x03001;&#x0767d;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x075c7;&#x0ff08;38%&#x0ff09;&#x03001;&#x08d2b;&#x08840;&#x0ff08;34%&#x0ff09;&#x03001;&#x08840;&#x05c0f;&#x0677f;&#x051cf;&#x05c11;&#x075c7;&#x0ff08;25%&#x0ff09;&#x0548c;&#x0538c;&#x098df;&#x0ff08;9%&#x0ff09;&#x03002;&#x0672a;&#x089c2;&#x05bdf;&#x05230;&#x053d1;&#x070ed;&#x06027;&#x04e2d;&#x06027;&#x07c92;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x075c7;&#x0548c;&#x06cbb;&#x07597;&#x076f8;&#x05173;&#x06b7b;&#x04ea1;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x08bba;</italic>.</bold> CBDCA&#x08054;&#x05408;&#x06bcf;&#x05468;&#x04e00;&#x06b21;nab&#x02010;PTX&#x06539;&#x0826f;&#x065b9;&#x06848;&#x05728;&#x0665a;&#x0671f;NSCLC&#x08001;&#x05e74;&#x060a3;&#x08005;&#x04e2d;&#x08868;&#x073b0;&#x051fa;&#x0663e;&#x08457;&#x07684;&#x07597;&#x06548;&#x0548c;&#x053ef;&#x063a5;&#x053d7;&#x07684;&#x06bd2;&#x06027;&#x03002;<bold><italic>The Oncologist</italic></bold> 2017;22:640&#x02013;e59</p></trans-abstract><counts><page-count count="5"/></counts></article-meta></front><body><sec id="onco12154-sec-0001"><title>Discussion</title><p>This prospective study was designed to investigate the efficacy and safety of modified CBDCA combined with weekly nab&#x02010;PTX as first&#x02010;line chemotherapy in elderly patients with advanced NSCLC. Socinski et al. analyzed the efficacy and toxicity of CBDCA combined with nab&#x02010;PTX in elderly patients (&#x02265;70 years old) in the CA031 study and revealed the ORR was 32% and the median OS was 19.9 months [<xref rid="onco12154-bib-0001" ref-type="ref">1</xref>]. An ORR of 50% and an OS of 17.5 months in the present study are consistent with the CA031 study, although our study was intended for patients &#x02265;75 years of age, and the median weekly dose intensity was less than that used in the CA031 study (45 mg/m<sup>2</sup> vs. 73.4 mg/m<sup>2</sup>).</p><fig fig-type="Figure" xml:lang="en" id="onco12154-fig-0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Tumor shrinkage by histological type. Blue bars: squamous cell carcinoma, <italic>n</italic>&#x02009;=&#x02009;18. Orange bars: adenocarcinoma, <italic>n</italic>&#x02009;=&#x02009;14.</p></caption><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12154-fig-0001"><alt-text>image</alt-text></graphic></fig><p>Quoix et al. recently reported on IFCT&#x02010;0501, a phase III study comparing CBDCA (AUC 6 mg/mL/min on day 1 every 4 weeks) plus PTX (90 mg/m<sup>2</sup> on days 1, 8, and 15 every 4 weeks) with monotherapy with vinorelbine or gemcitabine in elderly patients with advanced NSCLC [<xref rid="onco12154-bib-0002" ref-type="ref">2</xref>]. The median OS was significantly longer in the doublet group than in the monotherapy group. Similar to the IFCT&#x02010;0501 trial, we previously demonstrated the high efficacy of CBDCA (AUC 6 mg/mL/min on day 1 every 4 weeks) plus weekly PTX (70 mg/m<sup>2</sup> on days 1, 8, and 15 every 4 weeks) compared with single&#x02010;agent docetaxel for elderly patients with NSCLC [<xref rid="onco12154-bib-0003" ref-type="ref">3</xref>]. We have also reported on a randomized phase II trial of weekly PTX combined with CBDCA (same as above) versus standard PTX combined with CBDCA (210 mg/m<sup>2</sup> and AUC 6 mg/mL/min on day 1 every 3 weeks) for elderly patients with advanced NSCLC [<xref rid="onco12154-bib-0004" ref-type="ref">4</xref>]. Regarding the efficacy of CBDCA plus nab&#x02010;PTX, the ORR and PFS (50%, 6.4 months) attained are consistent with the results achieved with a CBDCA plus weekly PTX regimen in our previous two studies (55%, 6.0 months and 54%, 6.6 months, respectively) [<xref rid="onco12154-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12154-bib-0004" ref-type="ref">4</xref>].</p><p>Regarding the toxicity of modified carboplatin plus weekly nab&#x02010;paclitaxel, its adverse event (AE) profile was tolerable. Nonhematological toxicities were acceptable, with the most frequent AEs being anorexia, alopecia, and nausea. Also, the relatively lower incidences of sensory neuropathy resulting in the discontinuation of treatment were similar to those seen in patients treated with CBDCA plus nab&#x02010;PTX in the CA031 study [<xref rid="onco12154-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12154-bib-0005" ref-type="ref">5</xref>]. Our data support the feasibility of a modified regimen of CBDCA plus a lower dose of nab&#x02010;PTX for elderly patients. In addition to fewer AEs, because nab&#x02010;PTX does not contain solvents, unlike PTX, it is not usually necessary to take premedications, such as H1 and H2 blockers and steroids, to prevent allergic reactions prior to the administration of nab&#x02010;PTX [<xref rid="onco12154-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12154-bib-0007" ref-type="ref">7</xref>], [<xref rid="onco12154-bib-0008" ref-type="ref">8</xref>], [<xref rid="onco12154-bib-0009" ref-type="ref">9</xref>]. Therefore, nab&#x02010;PTX may be a more acceptable drug option than PTX for elderly lung cancer patients.
</p></sec><sec id="onco12154-sec-2007"><title>Trial Information</title><p><def-list id="onco12154-lp-8201"><def-item><term id="onco12154-li-0102"><bold>Disease</bold></term><def id="onco12154-li-0103"><p>Lung cancer &#x02013; NSCLC</p></def></def-item><def-item><term id="onco12154-li-0104"><bold>Stage of disease/treatment</bold></term><def id="onco12154-li-0105"><p>Metastatic/Advanced</p></def></def-item><def-item><term id="onco12154-li-0106"><bold>Prior therapy</bold></term><def id="onco12154-li-0107"><p>None</p></def></def-item><def-item><term id="onco12154-li-0108"><bold>Type of study &#x02013; 1</bold></term><def id="onco12154-li-0109"><p>Phase II</p></def></def-item><def-item><term id="onco12154-li-0110"><bold>Type of study &#x02013; 2</bold></term><def id="onco12154-li-0111"><p>Single arm</p></def></def-item><def-item><term id="onco12154-li-0112"><bold>Primary endpoint</bold></term><def id="onco12154-li-0113"><p>Overall response rate</p></def></def-item><def-item><term id="onco12154-li-0114"><bold>Secondary endpoint</bold></term><def id="onco12154-li-0115"><p>Progression free survival</p></def></def-item><def-item><term id="onco12154-li-0116"><bold>Secondary endpoint</bold></term><def id="onco12154-li-0117"><p>Overall survival</p></def></def-item><def-item><term id="onco12154-li-0118"><bold>Secondary endpoint</bold></term><def id="onco12154-li-0119"><p>Toxicity</p></def></def-item><def-item><term id="onco12154-li-0120"><bold>Additional details of endpoints or study design</bold></term><def id="onco12154-li-0121"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0122">Patients. Eligible patients were aged 75 years or older, with histologically or cytologically confirmed NSCLC that was classified as either clinical stage IIIb, IV, or a postoperative recurrence. Other eligibility criteria for patients included being previously untreated and having had at least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and an estimated life expectancy &#x0003e;12 weeks. Laboratory criteria included a hemoglobin concentration &#x02265;9 g/dL, a neutrophil count&#x02009;&#x02265;&#x02009;1,500/mm<sup>3</sup>, a platelet count &#x02265;100,000/mm<sup>3</sup>, aspartate transaminase and alanine transaminase &#x02264;100 IU/L, serum creatinine 1.5 mg/dL, and PaO<sub>2</sub> &#x02265;60 mmHg. Exclusion criteria included peripheral neuropathy with Common Terminology Criteria for Adverse Events (CTCAE) grade &#x02265;2, prior treatment with PTX as adjuvant chemotherapy, progressive brain metastases, or uncontrolled third&#x02010;space fluid retention prior to study entry. Patients were also excluded if they had an active infection, interstitial pneumonia, active lung fibrosis, an active synchronous cancer, or a history of allergy or hypersensitivity to drugs. An institutional review board at each hospital approved this study, and written, informed consent was obtained from all enrolled patients.</term><def id="onco12154-li-0123"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0124">Study Design and Treatment Plan. This multicenter, single arm, phase II study evaluated the efficacy and safety of a 75 mg/m<sup>2</sup> infusion of nab&#x02010;PTX on days 1, 8, and 15, followed by a CBDCA AUC of 6 mg/mL/min (per Calvert formula) on day 1 every 4 weeks, as first&#x02010;line chemotherapy in patients with advanced NSCLC. Treatment of at least four cycles was encouraged unless disease progression or unacceptable toxicities were observed. Second&#x02010;line chemotherapy or other treatments after this study were not prohibited by the protocol. Patients who had an epidermal growth factor receptor (EGFR) mutation received EGFR tyrosine kinase inhibitor after progression to this study treatment according to the protocol.</term><def id="onco12154-li-0125"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0126">Assessment of Efficacy and Safety Endpoints. The primary endpoint of this study was the ORR and the rate of complete response (CR) and/or partial response (PR) as confirmed by a blinded, centralized, independent review according to RECIST. Computed tomography scans were performed every 4 weeks from screening until disease progression. Secondary endpoints were PFS, OS, and toxicity profile. The follow&#x02010;up period was 18 months after the last patient enrollment.</term><def id="onco12154-li-0127"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0128">Statistical Methods. The minimum number of patients enrolled in the present study was 32 assuming an expected response rate (RR) of 40% and a threshold RR of 20% with an &#x003b1; error of 0.05 (one&#x02010;sided) and a &#x003b2; error of 0.2. Assuming that about 10% of patients would eventually not qualify, at least 35 patients needed to be recruited. The primary analysis of the ORR was planned in qualified patients, defined as receiving at least one course of nab&#x02010;PTX and CBDCA. PFS and OS were analyzed using Kaplan&#x02010;Meier methods. Safety analyses summarized AEs by maximum CTCAE grade, and whether or not they were serious, during the entire treatment period.</term><def id="onco12154-li-0129"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0130"><bold>Investigator's Analysis</bold></term><def id="onco12154-li-0131"><p>Active and should be pursued further</p></def></def-item></def-list>
</p></sec><sec id="onco12154-sec-0351"><title>Drug Information</title><p><def-list id="onco12154-lp-9201"><def-item><term id="onco12154-li-0132">Drug 1</term><def id="onco12154-li-0133"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0134">Generic/Working name</term><def id="onco12154-li-0135"><p>Nanoparticle albumin&#x02010;bound&#x02010;paclitaxel</p></def></def-item><def-item><term id="onco12154-li-0136">Trade name</term><def id="onco12154-li-0137"><p>Abraxane</p></def></def-item><def-item><term id="onco12154-li-0138">Company name</term><def id="onco12154-li-0139"><p>Taiho Pharma</p></def></def-item><def-item><term id="onco12154-li-0140">Drug type</term><def id="onco12154-li-0141"><p>Chemotherapy</p></def></def-item><def-item><term id="onco12154-li-0142">Drug class</term><def id="onco12154-li-0143"><p>Microtubule&#x02010;targeting agent</p></def></def-item><def-item><term id="onco12154-li-0144">Dose</term><def id="onco12154-li-0145"><p>75 milligrams (mg) per square meter (m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12154-li-0146">Route</term><def id="onco12154-li-0147"><p>IV</p></def></def-item><def-item><term id="onco12154-li-0148">Schedule of administration</term><def id="onco12154-li-0149"><p>Day 1, 8, and 15 every 4 weeks</p></def></def-item><def-item><term id="onco12154-li-0150">Drug 2</term><def id="onco12154-li-0151"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12154-li-0152">Generic/Working name</term><def id="onco12154-li-0153"><p>Carboplatin</p></def></def-item><def-item><term id="onco12154-li-0154">Trade name</term><def id="onco12154-li-0155"><p>Paraplatin</p></def></def-item><def-item><term id="onco12154-li-0156">Company name</term><def id="onco12154-li-0157"><p>Bristol&#x02010;Myers Squibb</p></def></def-item><def-item><term id="onco12154-li-0158">Drug type</term><def id="onco12154-li-0159"><p>Chemotherapy</p></def></def-item><def-item><term id="onco12154-li-0160">Drug class</term><def id="onco12154-li-0161"><p>Platinum compound</p></def></def-item><def-item><term id="onco12154-li-0162">Dose</term><def id="onco12154-li-0163"><p>AUC 6 mg/mL/min</p></def></def-item><def-item><term id="onco12154-li-0164">Route</term><def id="onco12154-li-0165"><p>IV</p></def></def-item><def-item><term id="onco12154-li-0166">Schedule of administration</term><def id="onco12154-li-0167"><p>Day 1 every 4 weeks</p></def></def-item></def-list>
</p></sec><sec id="onco12154-sec-2309"><title>Patient Characteristics for Phase II Control Arm</title><p><def-list id="onco12154-lp-1261"><def-item><term id="onco12154-li-0168">Number of patients, male</term><def id="onco12154-li-0169"><p>27</p></def></def-item><def-item><term id="onco12154-li-0170">Number of patients, female</term><def id="onco12154-li-0171"><p>5</p></def></def-item><def-item><term id="onco12154-li-0172">Stage</term><def id="onco12154-li-0173"><p>IIIb: 7</p><p>IV: 18</p><p>Postoperative recurrence: 7</p></def></def-item><def-item><term id="onco12154-li-0174">Age</term><def id="onco12154-li-0175"><p>Median (range): 78(75&#x02013;86)</p></def></def-item><def-item><term id="onco12154-li-0176">Number of prior systemic therapies</term><def id="onco12154-li-0177"><p>Median (range): 0</p></def></def-item><def-item><term id="onco12154-li-0178">Performance status: ECOG</term><def id="onco12154-li-0179"><p>&#x000a0;</p><p>0 &#x02014; 16</p><p>1 &#x02014; 16</p><p>2 &#x02014;</p><p>3 &#x02014;</p><p>unknown &#x02014;</p></def></def-item><def-item><term id="onco12154-li-0180">Other: EGFR mutation status</term><def id="onco12154-li-0181"><p>Mutant: 2</p><p>Wild: 16</p><p>Unknown: 14</p></def></def-item><def-item><term id="onco12154-li-0182">Cancer types or histologic subtypes</term><def id="onco12154-li-0183"><p>Adenocarcinoma: 14</p><p>Squamous cell carcinoma: 18</p></def></def-item></def-list>
</p></sec><sec id="onco12154-sec-1222"><title>Primary Assessment Method for Phase II Control Arm</title><p><def-list id="onco12154-lp-1381"><def-item><term id="onco12154-li-0184">Number of patients screened</term><def id="onco12154-li-0185"><p>35</p></def></def-item><def-item><term id="onco12154-li-0186">Number of patients enrolled</term><def id="onco12154-li-0187"><p>35</p></def></def-item><def-item><term id="onco12154-li-0188">Number of patients evaluable for toxicity</term><def id="onco12154-li-0189"><p>32</p></def></def-item><def-item><term id="onco12154-li-0190">Number of patients evaluated for efficacy</term><def id="onco12154-li-0191"><p>32</p></def></def-item><def-item><term id="onco12154-li-0192">Response assessment CR</term><def id="onco12154-li-0193"><p><italic>n</italic>&#x02009;=&#x02009;1 (3.1%)</p></def></def-item><def-item><term id="onco12154-li-0194">Response assessment PR</term><def id="onco12154-li-0195"><p><italic>n</italic>&#x02009;=&#x02009;15 (46.9%)</p></def></def-item><def-item><term id="onco12154-li-0196">Response assessment SD</term><def id="onco12154-li-0197"><p><italic>n</italic>&#x02009;=&#x02009;14 (43.8%)</p></def></def-item><def-item><term id="onco12154-li-0198">Response assessment PD</term><def id="onco12154-li-0199"><p><italic>n</italic>&#x02009;=&#x02009;2 (6.3%)</p></def></def-item><def-item><term id="onco12154-li-0200">Response assessment OTHER</term><def id="onco12154-li-0201"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12154-li-0202">(Median) duration assessments PFS</term><def id="onco12154-li-0203"><p>6.4 months, CI: 4.8&#x02013;8.0</p></def></def-item><def-item><term id="onco12154-li-0204">(Median) duration assessments OS</term><def id="onco12154-li-0205"><p>17.5 months, CI: 11.9&#x02013;23.1</p></def></def-item></def-list>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12154-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12154-sec-6722"><title>Assessment, Analysis, and Discussion</title><p><def-list id="onco12154-lp-7209"><def-item><term id="onco12154-li-0206">Completion</term><def id="onco12154-li-0207"><p>Study completed</p></def></def-item><def-item><term id="onco12154-li-0208">Pharmacokinetics/Pharmacodynamics</term><def id="onco12154-li-0209"><p>Not Collected</p></def></def-item><def-item><term id="onco12154-li-0210">Investigator's assessment</term><def id="onco12154-li-0211"><p>Active and should be pursued further</p></def></def-item></def-list>
</p></sec><sec id="onco12154-sec-0006"><p>Lung cancer is the most common cause of death from cancer in the elderly population. With many countries facing an aging population, the incidence of lung cancer in this age group is expected to increase. Consequently, it has become increasingly important to establish more effective treatments for elderly patients with advanced non&#x02010;small cell lung cancer (NSCLC). A recent IFCT&#x02010;0501 trial demonstrated that carboplatin (CBDCA) combined with weekly paclitaxel (PTX) would be advantageous, compared with vinorelbine or gemcitabine monotherapy, for elderly patients with previously untreated, advanced NSCLC [<xref rid="onco12154-bib-0002" ref-type="ref">2</xref>]. Subsequently, the CA031 trial suggested that weekly nanoparticle albumin&#x02010;bound&#x02010;PTX (nab&#x02010;PTX) was superior in efficacy and safety compared with PTX once every 3 weeks when combined with CBDCA [<xref rid="onco12154-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12154-bib-0005" ref-type="ref">5</xref>]. In addition, a subgroup analysis of elderly patients in the CA031 trial yielded very promising data (a 34% overall response rate [ORR] and 8 months of progression&#x02010;free survival [PFS]), whereas in a Japanese subgroup analysis, many cases required the omission of treatments as well as a reduction in doses [<xref rid="onco12154-bib-0010" ref-type="ref">10</xref>]. We therefore conducted this multicenter, nonrandomized, open&#x02010;label, phase II trial to prospectively evaluate the efficacy and tolerability of a modified CBDCA plus weekly nab&#x02010;PTX regimen for elderly patients with previously untreated, advanced NSCLC. The ORR met our primary endpoint and supported the favorable efficacy of this combination among an elderly population, as found in the CA031 trial [<xref rid="onco12154-bib-0005" ref-type="ref">5</xref>].</p><p>We also evaluated the ORR by histologic type. Satouchi et al. reported that a Japanese subset analysis of the CA031 study showed more effectiveness in the squamous cell carcinoma subset than in nonsquamous cell carcinoma [<xref rid="onco12154-bib-0010" ref-type="ref">10</xref>]. Although a similar tendency was shown in this study, because of the small sample size, a significant difference was not observed between adenocarcinoma and squamous cell carcinoma in terms of ORR and PFS. Recently, several studies have confirmed the effectiveness of nab&#x02010;PTX with CBDCA in patients with squamous cell carcinoma [<xref rid="onco12154-bib-0011" ref-type="ref">11</xref>]. Further study is needed to determine the difference in effects for both histological types.</p><p>The present study had several limitations. First, this study used a small sample size and, for this reason, future phase III studies will be required to evaluate the effectiveness of this modified regimen, although promising results were obvious in this study. Concerning this limitation, the CAPITAL study, a randomized phase III trial of CBDCA plus nab&#x02010;PTX versus docetaxel for squamous NSCLC in the elderly, is ongoing in Japan. Second, the present study lacked a quality&#x02010;of&#x02010;life (QoL) assessment. Most elderly patients with advanced NSCLC do not have curative treatment options, and, therefore, the goal of therapy for such patients is a prolongation of survival without negatively impacting QoL. From this perspective, we plan to evaluate QoL in a future, randomized phase III trial of modified CBDCA plus nab&#x02010;PTX for elderly patients with advanced NSCLC.</p><p>In conclusion, weekly nab&#x02010;PTX (75 mg/m<sup>2</sup>) in combination with CBDCA (AUC 6 mg/mL/min) in elderly patients with previously untreated, advanced NSCLC showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity. Therefore, nab&#x02010;PTX offers several distinct advantages over conventional PTX when combined with CBDCA. Based on our results, even if the high cost of nab&#x02010;PTX is considered, we believe that a modified CBDCA plus weekly nab&#x02010;PTX regimen should be used for elderly patients regarding efficacy and tolerability. Future phase III studies will be needed to further evaluate the role of weekly nab&#x02010;PTX in combination with CBDCA for such patients.</p></sec></body><back><ack id="onco12154-sec-0007"><title>Acknowledgements</title><p>The authors thank all patients, families, and investigators participating in the NJLCG1301 study.</p></ack><fn-group><fn fn-type="other" id="onco12154-note-2230"><p><bold>UMIN&#x02010;CTR Identifier</bold>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/UMIN000010324">UMIN000010324</ext-link></p><p><bold>Sponsor</bold>: North Japan Lung Cancer Study Group</p><p><bold>Principal Investigator</bold>: Eisaku Miyauchi</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12154-note-9292"><p><ext-link ext-link-type="uri" xlink:href="http://clinicaltrialresults.theoncologist.com/search/results">Click here to access other published clinical trials</ext-link>.</p></fn></fn-group><sec id="onco12154-sec-0008" sec-type="disclosure"><title>Disclosures</title><p><bold>Akira Inoue:</bold> Taiho (H); <bold>Shunichi Sugawara:</bold> AstraZeneca, Chugai, Nippon Boehringer Ingelheim, Pfizer, Taiho, Eli Lilly and Company, Novartis, Kyowa Hakko Kirin, Bristol&#x02010;Myers Squibb, Ono (H); <bold>Makoto Maemondo:</bold> Bristol&#x02010;Myers Squibb (H). The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12154-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12154-cit-0001">
<string-name><surname>Socinski</surname>
<given-names>MA</given-names></string-name>, 
<string-name><surname>Langer</surname>
<given-names>CJ</given-names></string-name>, 
<string-name><surname>Okamoto</surname>
<given-names>I</given-names></string-name> et al. <article-title>Safety and efficacy of weekly nab&#x000ae;&#x02010;paclitaxel in combination with carboplatin as first&#x02010;line therapy in elderly patients with advanced non&#x02010;small&#x02010;cell lung cancer</article-title>. <source>Ann Oncol</source>
<year>2013</year>;<volume>24</volume>:<fpage>314</fpage>&#x02013;<lpage>321</lpage>.
<pub-id pub-id-type="pmid">23123509</pub-id></mixed-citation></ref><ref id="onco12154-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12154-cit-0002">
<string-name><surname>Quoix</surname>
<given-names>E</given-names></string-name>, 
<string-name><surname>Zalcman</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Oster</surname>
<given-names>JP</given-names></string-name> et al. <article-title>Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non&#x02010;small&#x02010;cell lung cancer: IFCT&#x02010;0501 randomised, phase 3 trial</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>378</volume>:<fpage>1079</fpage>&#x02013;<lpage>1088</lpage>.
<pub-id pub-id-type="pmid">21831418</pub-id></mixed-citation></ref><ref id="onco12154-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12154-cit-0003">
<string-name><surname>Maemondo</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Inoue</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Sugawara</surname>
<given-names>S</given-names></string-name> et al. <article-title>Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non&#x02010;small cell lung cancer: North Japan Lung Cancer Group Trial 0801</article-title>. <source>The Oncologist</source>
<year>2014</year>;<volume>19</volume>:<fpage>352</fpage>&#x02013;<lpage>353</lpage>.
<pub-id pub-id-type="pmid">24682465</pub-id></mixed-citation></ref><ref id="onco12154-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12154-cit-0004">
<string-name><surname>Sakakibara</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Inoue</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Sugawara</surname>
<given-names>S</given-names></string-name> et al. <article-title>Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non&#x02010;small&#x02010;cell lung cancer</article-title>. <source>Ann Oncol</source>
<year>2010</year>;<volume>21</volume>:<fpage>795</fpage>&#x02013;<lpage>799</lpage>.
<pub-id pub-id-type="pmid">19815651</pub-id></mixed-citation></ref><ref id="onco12154-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12154-cit-0005">
<string-name><surname>Socinski</surname>
<given-names>MA</given-names></string-name>, 
<string-name><surname>Bondarenko</surname>
<given-names>I</given-names></string-name>, 
<string-name><surname>Karaseva</surname>
<given-names>NA</given-names></string-name> et al. <article-title>Weekly nab&#x02010;paclitaxel in combination with carboplatin versus solvent&#x02010;based paclitaxel plus carboplatin as first&#x02010;line therapy in patients with advanced non&#x02010;small&#x02010;cell lung cancer: Final results of a phase III trial</article-title>. <source>J Clin Oncol</source>
<year>2012</year>;<volume>30</volume>:<fpage>2055</fpage>&#x02013;<lpage>2062</lpage>.
<pub-id pub-id-type="pmid">22547591</pub-id></mixed-citation></ref><ref id="onco12154-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12154-cit-0006">
<string-name><surname>Ten Tije</surname>
<given-names>AJ</given-names></string-name>, 
<string-name><surname>Verweij</surname>
<given-names>J</given-names></string-name>, 
<string-name><surname>Loos</surname>
<given-names>WJ</given-names></string-name> et al. <article-title>Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy</article-title>. <source>Clin Pharmacokinet</source>
<year>2003</year>;<volume>42</volume>:<fpage>665</fpage>&#x02013;<lpage>685</lpage>.
<pub-id pub-id-type="pmid">12844327</pub-id></mixed-citation></ref><ref id="onco12154-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12154-cit-0007">
<string-name><surname>Desai</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>Trieu</surname>
<given-names>V</given-names></string-name>, 
<string-name><surname>Yao</surname>
<given-names>Z</given-names></string-name> et al. <article-title>Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor&#x02010;free, albumin&#x02010;bound paclitaxel, ABI&#x02010;007, compared with cremophor&#x02010;based paclitaxel</article-title>. <source>Clin Cancer Res</source>
<year>2006</year>;<volume>12</volume>:<fpage>1317</fpage>&#x02013;<lpage>1324</lpage>.
<pub-id pub-id-type="pmid">16489089</pub-id></mixed-citation></ref><ref id="onco12154-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12154-cit-0008">
<string-name><surname>Gupta</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>Hatoum</surname>
<given-names>H</given-names></string-name>, 
<string-name><surname>Dy</surname>
<given-names>GK.</given-names></string-name>
<article-title>First line treatment of advanced non&#x02010;small&#x02010;cell lung cancer&#x02010;specific focus on albumin bound paclitaxel</article-title>. <source>Int J Nanomedicine</source>
<year>2014</year>;<volume>9</volume>:<fpage>209</fpage>&#x02013;<lpage>221</lpage>.
<pub-id pub-id-type="pmid">24399877</pub-id></mixed-citation></ref><ref id="onco12154-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12154-cit-0009">
<string-name><surname>Hirsh</surname>
<given-names>V.</given-names></string-name>
<article-title>Nab&#x02010;paclitaxel for the management of patients with advanced non&#x02010;small&#x02010;cell lung cancer</article-title>. <source>Expert Rev Anticancer Ther</source>
<year>2014</year>;<volume>14</volume>:<fpage>129</fpage>&#x02013;<lpage>141</lpage>.
<pub-id pub-id-type="pmid">24467217</pub-id></mixed-citation></ref><ref id="onco12154-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12154-cit-0010">
<string-name><surname>Satouchi</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Okamoto</surname>
<given-names>I</given-names></string-name>, 
<string-name><surname>Sakai</surname>
<given-names>H</given-names></string-name> et al. <article-title>Efficacy and safety of weekly nab&#x02010;paclitaxel plus carboplatin in patients with advanced non&#x02010;small cell lung cancer</article-title>. <source>Lung Cancer</source>
<year>2013</year>;<volume>81</volume>:<fpage>97</fpage>&#x02013;<lpage>101</lpage>.
<pub-id pub-id-type="pmid">23545279</pub-id></mixed-citation></ref><ref id="onco12154-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12154-cit-0011">
<string-name><surname>Simon</surname>
<given-names>GR.</given-names></string-name>
<article-title>Nab&#x02010;Paclitaxel for the treatment of advanced squamous non&#x02010;small&#x02010;cell lung cancer: A comprehensive update</article-title>. <source>Clin Lung Cancer</source>
<year>2014</year>;<volume>15</volume>:<fpage>391</fpage>&#x02013;<lpage>397</lpage>.
<pub-id pub-id-type="pmid">25246384</pub-id></mixed-citation></ref></ref-list></back></article>